UniQure (QURE) said Monday that it has completed enrollment in the first cohort of patients of the phase 1/2a trial of its gene therapy candidate, AMT-191, for the treatment of Fabry disease.
The firm also said the Independent Data Monitoring Committee recommended proceeding with enrollment in the second cohort after it found no significant safety concerns following a safety data review from the first cohort's initial two patients.
The company said it expects to initiate enrollment of second dose cohort in the first quarter of 2025.
Price: 15.47, Change: -0.27, Percent Change: -1.72
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.